Corporate History Timeline
Thirty Years of Advancing Therapeutics and Improving Lives
Millions of people around the world are living healthier lives because of therapies developed by Gilead.
The U.S. Food and Drug Administration approves Biktarvy®, a once-daily single tablet regimen (STR) for the treatment of adults with HIV-1 infection.
Gilead COMPASS Initiative® launches to help address HIV/AIDS in the Southern United States. Through the COMPASS (COMmitment to Partnership in Addressing HIV/AIDS in Southern States) program, Gilead has pledged $100 million over 10 years to support efforts to reduce HIV-related stigma and inequalities that disproportionately impact people living in the South.
The U.S. Food and Drug Administration approves Yescarta®, a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.
The U.S. Food and Drug Administration approves Vosevi®, the first pan-genotypic single tablet regimen for adults with chronic hepatitis C infection who failed certain direct-acting antiviral regimens.
Gilead employees around the world participate in the company's first Week of Service. This worldwide series of volunteer events supports local communities in honor of Gilead's 30th anniversary.
On April 7, 2017, the U.S. FDA approves Harvoni® and Sovaldi® for adolescents ages 12 years or older with chronic hepatitis C virus, the first step in helping the medicine reach younger people living with HCV.
Gilead-developed HIV medicines reach more than 10 million people in the developing world. The company’s licensing agreements with generic drug manufacturers play a key role in expanding access to Gilead-based HIV medicines in the developing world.
Pictured: Gilead employees come together to form a red ribbon in recognition of World AIDS Day on Dec. 1.
The U.S. Food and Drug Administration approves Vemlidy®, a once-daily treatment for adults with chronic hepatitis B virus (HBV) infection with compensated liver disease.
On Aug. 22, 2016, the European Commission grants marketing authorization of Truvada tablets for use as PrEP, in combination with safer sex practices such as condoms, to reduce the risk of sexually acquired HIV in adults with high risk of infection.
The approval applies to all 28 European Union countries and will help make Truvada for PrEP available to more people at risk of HIV infection across the EU.
The U.S. Food and Drug Administration approves Epclusa®, the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection.
Employees participate in San Francisco Pride parade. The LGBT Alliance – an Employee Resource Group – creates the company’s first Pride float. Employees, family members and friends ride on and walk next to the science-themed float.
The U.S. Food and Drug Administration approves Descovy®, a fixed-dose combination for HIV-1 infection.
The U.S. Food and Drug Administration approves Odefsey®, a complete once-daily, single tablet regimen for HIV-1 infection.
The U.S. Food and Drug Administration approves Genvoya®, a complete once-daily, single tablet regimen for HIV-1 infection.
The U.S. Food and Drug Administration approves Harvoni® for the treatment of chronic hepatitis C (CHC) genotype 1 infection in adults.
The U.S. Food and Drug Administration approves Tybost® for use in combination with other antiretroviral agents for the treatment of HIV-1 infection.
The U.S. Food and Drug Administration approves Vitekta® as part of combination antiretroviral therapy in adults with HIV-1 infection.
Generic licensing agreements signed with Indian generic partners help increase access to Gilead hepatitis C medicines in developing countries.
The initial agreements provide treatment access to 91 developing countries that together account for more than 100 million people living with hepatitis C.
The U.S. Food and Drug Administration approves Zydelig® (idelalisib) for the treatment of certain patients with relapsed chronic lymphocytic leukemia (CLL) in combination with rituximab and as monotherapy for patients with relapsed follicular B-cell non-Hodgkin lymphoma (FL) and small lymphocytic lymphoma (SLL) who have received at least two prior systemic therapies.
FOCUS program reaches 1 million people with HIV testing. The public health initiative, established in 2010, enables partners to make system-level changes to bring screening and linkage to care efforts into alignment with federal and local health guidelines. FOCUS later expands to include screening and linkage to care for hepatitis B and C.
Pictured: Map of FOCUS cities.
The U.S. Food and Drug Administration approves Sovaldi® for the treatment of chronic hepatitis C (CHC) as a component of a combination antiviral treatment regimen.
Gilead subsequently introduces three other sofosbuvir-containing regimens. Millions of people around the world have received a sofosbuvir-based medicine and the vast majority of them have been cured.
The European Commission approves Vitekta®, an integrase inhibitor, for use in combination therapy on Nov. 18, 2013. The medicine was approved by the FDA on Sept. 13, 2014.
The European Commission approves Tybost® on Sept. 25, 2013 as a boosting agent for certain HIV medicines. The medicine is approved by the FDA almost exactly one year later on Sept. 24, 2014.
Gilead receives Patents for Humanity award. This award, which is presented by the United States Patent and Trademark Office, is given to Gilead in recognition of the company’s work to bring life-saving technologies to people in underserved regions of the world.
The U.S. Food and Drug Administration approves Stribild®, a complete once-daily, single tablet regimen for HIV-1 infection in treatment-naïve adults.
The U.S. Food and Drug Administration approves Truvada®, in combination with safer sex practices, to reduce the risk of sexually acquired HIV-1 infection in adults at high risk. Truvada is the first and only medicine available for the prevention of HIV.
The FDA approves Viread® for use in children living with HIV as young as 2 years of age. The approval includes three lower-strength, once-daily tablets for children 6-12, as well as an oral powder formulation for children ages 2-5.
European Medicines Agency approves Eviplera® for the treatment of HIV.
The U.S. Food and Drug Administration approves Complera®, a complete once-daily, single-tablet regimen for HIV-1 infection in treatment-naïve adults.
The U.S. Food and Drug Administration approves Cayston® for the improvement of respiratory symptoms in cystic fibrosis patients with Pseudomonas aeruginosa.
The FDA expands the indication for Ranexa on Nov. 6, 2008, approving it as a first-line treatment for chronic angina.
The U.S. Food and Drug Administration approves Viread® for chronic hepatitis B in adults.
European Medicines Agency approves Viread® for the treatment of chronic hepatitis B.
On April 10, 2008, the FDA approves Lexiscan, developed by CV Therapeutics, for use as a stress agent in radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress.
European Medicines Agency approves Atripla® for the treatment of HIV.
Atripla® approved by Health Canada.
The U.S. Food and Drug Administration approves Letairis® for the treatment of pulmonary arterial hypertension.
The treatment guidelines from the U.S. Department of Health and Human Services list Truvada® as the preferred Nucleoside Reverse Transcriptase (NRTI) backbone of choice for treatment-naïve patients.
The U.S. Food and Drug Administration approves Atripla®, the first once-daily single tablet regimen for adults with HIV-1 infection.
The approval of Atripla marked a dramatic transformation in HIV care, which once required complex treatment of multiple pills taken at different times throughout the day.
The U.S. Food and Drug Administration approves Ranexa® for the treatment of chronic angina.
European Medicines Agency approves Truvada® for the treatment of HIV.
The U.S. Food and Drug Administration approves Macugen® for age-related macular degeneration.
Truvada is added to Gilead's Access Program and U.S. Advancing Access Program.
The U.S. Food and Drug Administration approves Truvada®, a one-tablet, once-a-day fixed-dose co-formulation of Emtriva and Viread for HIV combination therapy.
European Medicines Agency approves Emtriva® for the treatment of HIV.
The U.S. Food and Drug Administration approves Emtriva® for the treatment of HIV.
European Medicines Agency approves Hepsera® for the treatment of chronic
The U.S. Food and Drug Administration approves Hepsera® for the treatment of chronic hepatitis B.
European Medicines Agency approves Viread for the treatment of HIV infection.
The U.S. Food and Drug Administration approves Viread® for the treatment of HIV infection
The U.S. Food and Drug Administration approves AmBisome® for the treatment of cryptococcal meningitis in HIV-infected patients.
The U.S. Food and Drug Administration approves Tamiflu® for the treatment of influenza A and B in adults.
Gilead establishes its first patient assistance program. The program facilitates access to Vistide, a medicine for the eye infection cytomegalovirus retinitis that was once common among people living with HIV. The program later became part of the U.S. Advancing Access® Program, which launched in July 2004, to aid people taking certain Gilead medicines who do not have insurance or who need financial assistance.
The FDA approves Vistide on June 26, 1996 for cytomegalovirus (CMV) retinitis.
Gilead begins development of small-molecule antiviral therapeutics. The company licenses nucleotide compounds discovered by Antonín Holý from the Institute of Organic Chemistry and Biochemistry and Erik De Clercq from the Rega Institute for Medical Research. The research paves the way for the development of Gilead’s innovative treatments for HIV and hepatitis B.
Pictured: Researchers Antonín Holý and Erik De Clercq.
AmBisome® becomes available in Ireland. AmBisome comes to Gilead through the acquisition of NeXstar Pharmaceuticals in 1999. Since then, more than 1 million people have received AmBisome. The medicine remains the gold standard for treating a broad spectrum of potentially lethal fungal infections and a single dose can cure people of the parasitic disease visceral leishmaniasis, which is endemic in certain parts of the world.
Gilead founded as Oligogen on June 22. The name changes to Gilead Sciences the following year.
Pictured: First company photo.